Patent ID: 11969412
Assignee: POOLBEG PHARMA (UK) LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating hypercytokinemia in a human or animal patient in need thereof, or a prophylactic method of treating a human or animal patient at risk of developing hypercytokinemia after an immune response has been triggered, comprising administering to the patient a therapeutically or prophylactically effective amount of a p38 MAP kinase inhibitor, wherein:
the p38 MAP kinase inhibitor is of Formula I or a pharmaceutically acceptable salt or solvate thereof:, wherein R is C1-3 alkyl, optionally substituted by one or more halo, NR1R2 hydroxy, and R1 and R2 are independently H, halo or C1-3 alkyl, optionally substituted by one or more F.